[1] |
Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria[J]. Allergy, 2022,77(3):734⁃766. doi: 10.1111/all.15090.
|
[2] |
Pozderac I, Lugović⁃Mihić L, Artuković M, et al. Chronic inducible urticaria: classification and prominent features of physical and non⁃physical types[J]. Acta Dermatovenerol Alp Pannonica Adriat, 2020,29(3):141⁃148. doi: 10.15570/actaapa. 2020.29.
|
[3] |
Maurer M, Metz M, Brehler R, et al. Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence[J]. J Allergy Clin Immunol, 2018,141(2):638⁃649. doi: 10.1016/j.jaci.2017.06.032.
|
[4] |
中华医学会皮肤性病学分会荨麻疹研究中心. 中国荨麻疹诊疗指南(2022版)[J]. 中华皮肤科杂志, 2022,55(12):1041⁃1049. doi: 10.35541/cjd.20220609.
|
[5] |
Heinzerling L, Mari A, Bergmann KC, et al. The skin prick test ⁃ European standards[J]. Clin Transl Allergy, 2013,3(1):3. doi: 10.1186/2045⁃7022⁃3⁃3.
|
[6] |
Qian T, Li S, Chen Q, et al. Efficacy and safety of ebastine dose escalation in chronic urticaria: a prospective study[J]. Dermatol Ther, 2022,35(5):e15386. doi: 10.1111/dth.15386.
|
[7] |
Magerl M, Altrichter S, Borzova E, et al. The definition, diagnostic testing, and management of chronic inducible urticarias⁃The EAACI/GA2LEN/EDF/UNEV consensus recommendations 2016 update and revision[J]. Allergy, 2016,71(6):780⁃802. doi: 10.1111/all.12884.
|
[8] |
Zhong H, Song Z, Chen W, et al. Chronic urticaria in Chinese population: a hospital⁃based multicenter epidemiological study[J]. Allergy, 2014,69(3):359⁃364. doi: 10.1111/all.12338.
|
[9] |
Fukunaga A, Washio K, Hatakeyama M, et al. Cholinergic urticaria: epidemiology, physiopathology, new categorization, and management[J]. Clin Auton Res, 2018,28(1):103⁃113. doi: 10.1007/s10286⁃017⁃0418⁃6.
|
[10] |
Pezzolo E, Peroni A, Gisondi P, et al. Heat urticaria: a revision of published cases with an update on classification and management[J]. Br J Dermatol, 2016,175(3):473⁃478. doi: 10. 1111/bjd.14543.
|
[11] |
Maltseva N, Borzova E, Fomina D, et al. Cold urticaria ⁃ what we know and what we do not know[J]. Allergy, 2021,76(4):1077⁃1094. doi: 10.1111/all.14674.
|
[12] |
Schoepke N, Młynek A, Weller K, et al. Symptomatic dermographism: an inadequately described disease[J]. J Eur Acad Dermatol Venereol, 2015,29(4):708⁃712. doi: 10.1111/jdv.12661.
|
[13] |
Konstantinou GN, Asero R, Maurer M, et al. EAACI/GA2LEN task force consensus report: the autologous serum skin test in urticaria[J]. Allergy, 2009,64(9):1256⁃1268. doi: 10.1111/j. 1398⁃9995.2009.02132.x.
|
[14] |
Chen QQ, Zhong H, Shong ZQ, et al. Cold contact urticaria combined with cold⁃dependent dermographism and serum autoreactivity: what have we ignored?[J]. Int J Dermatol Venereol, 2019,2(1):43⁃44. doi:10.3760/cma.j.issn.2096⁃5540.2019.01. 010.
|
[15] |
Fukunaga A, Bito T, Tsuru K, et al. Responsiveness to autologous sweat and serum in cholinergic urticaria classifies its clinical subtypes[J]. J Allergy Clin Immunol, 2005,116(2):397⁃402. doi: 10.1016/j.jaci.2005.05.024.
|
[16] |
Fukunaga A, Oda Y, Imamura S, et al. Cholinergic urticaria: subtype classification and clinical approach[J]. Am J Clin Dermatol, 2023,24(1):41⁃54. doi: 10.1007/s40257⁃022⁃00728⁃6.
|
[17] |
Dressler C, Werner RN, Eisert L, et al. Chronic inducible urticaria: a systematic review of treatment options[J]. J Allergy Clin Immunol, 2018,141(5):1726⁃1734. doi: 10.1016/j.jaci.2018.01.031.
|
[18] |
Kirchhof MG, de Gannes GC. Atopy associated with positive patch test and possible allergic contact dermatitis[J]. J Cutan Med Surg, 2018,22(4):405⁃410. doi: 10.1177/1203475418758988.
|
[19] |
Karakaya G, Ozturk AB, Kalyoncu AF. Prediction of atopy by skin prick tests in patients with asthma and/or persistent rhinitis[J]. Allergol Immunopathol (Madr), 2012,40(1):37⁃40. doi: 10.1016/j.aller.2011.01.005.
|
[20] |
Garcia⁃Marcos L, Sanchez⁃Solis M, Martinez⁃Torres AE, et al. Phadiatop compared to skin⁃prick test as a tool for diagnosing atopy in epidemiological studies in schoolchildren[J]. Pediatr Allergy Immunol, 2007,18(3):240⁃244. doi: 10.1111/j.1399⁃3038.2006.00508.x.
|
[21] |
Kulthanan K, Wachirakaphan C. Prevalence and clinical characteristics of chronic urticaria and positive skin prick testing to mites[J]. Acta Derm Venereol, 2008,88(6):584⁃588. doi: 10.2340/00015555⁃0546.
|
[22] |
Shalom G, Magen E, Dreiher J, et al. Chronic urticaria and atopic disorders: a cross⁃sectional study of 11 271 patients[J]. Br J Dermatol, 2017,177(4):e96⁃e97. doi: 10.1111/bjd.15347.
|
[23] |
Altrichter S, Koch K, Church MK, et al. Atopic predisposition in cholinergic urticaria patients and its implications[J]. J Eur Acad Dermatol Venereol, 2016,30(12):2060⁃2065. doi: 10.1111/jdv. 13765.
|
[24] |
Kulthanan K, Ungprasert P, Tuchinda P, et al. Symptomatic dermographism: a systematic review of treatment options[J]. J Allergy Clin Immunol Pract, 2020,8(9):3141⁃3161. doi: 10.1016/j.jaip.2020.05.016.
|
[25] |
Maurer M, Schütz A, Weller K, et al. Omalizumab is effective in symptomatic dermographism⁃results of a randomized placebo⁃controlled trial[J]. J Allergy Clin Immunol, 2017,140(3):870⁃873.e5. doi: 10.1016/j.jaci.2017.01.042.
|
[26] |
Giménez⁃Arnau AM, Ribas⁃Llauradó C, Mohammad⁃Porras N, et al. IgE and high⁃affinity IgE receptor in chronic inducible urticaria, pathogenic, and management relevance[J]. Clin Transl Allergy, 2022,12(2):e12117. doi: 10.1002/clt2.12117.
|
[27] |
Metz M, Schütz A, Weller K, et al. Omalizumab is effective in cold urticaria⁃results of a randomized placebo⁃controlled trial[J]. J Allergy Clin Immunol, 2017,140(3):864⁃867.e5. doi: 10.1016/j.jaci.2017.01.043.
|
[28] |
Kozel MM, Mekkes JR, Bossuyt PM, et al. Natural course of physical and chronic urticaria and angioedema in 220 patients[J]. J Am Acad Dermatol, 2001,45(3):387⁃391. doi: 10.1067/mjd.2001.116217.
|
[29] |
Bal F, Kahveci M, Soyer O, et al. Chronic inducible urticaria subtypes in children: clinical features and prognosis[J]. Pediatr Allergy Immunol, 2021,32(1):146⁃152. doi: 10.1111/pai.13324.
|
[30] |
Abajian M, Młynek A, Maurer M. Physical urticaria[J]. Curr Allergy Asthma Rep, 2012,12(4):281⁃287. doi: 10.1007/s11882⁃012⁃0269⁃0.
|
[31] |
Fleischer M, Grabbe J. Physical urticaria[J]. Hautarzt, 2004,55(4):344⁃349. doi: 10.1007/s00105⁃004⁃0691⁃x.
|
[32] |
Zuberbier T, Maurer M. Urticaria: current opinions about etiology, diagnosis and therapy[J]. Acta Derm Venereol, 2007,87(3):196⁃205. doi: 10.2340/00015555⁃0240.
|
[33] |
Möller A, Henning M, Zuberbier T, et al. Epidemiology and clinical aspects of cold urticaria[J]. Hautarzt, 1996,47(7):510⁃514. doi: 10.1007/s001050050461.
|
[34] |
Wanderer AA, Grandel KE, Wasserman SI, et al. Clinical characteristics of cold⁃induced systemic reactions in acquired cold urticaria syndromes: recommendations for prevention of this complication and a proposal for a diagnostic classification of cold urticaria[J]. J Allergy Clin Immunol, 1986,78(3 Pt 1):417⁃423. doi: 10.1016/0091⁃6749(86)90027⁃8.
|
[35] |
Kim JE, Eun YS, Park YM, et al. Clinical characteristics of cholinergic urticaria in Korea[J]. Ann Dermatol, 2014,26(2):189⁃194. doi: 10.5021/ad.2014.26.2.189.
|
[36] |
Moore⁃Robinson M, Warin RP. Some clinical aspects of cholinergic urticaria[J]. Br J Dermatol, 1968,80(12):794⁃799. doi: 10.1111/j.1365⁃2133.1968.tb11948.x.
|